The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of tumor burden or focality in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer on response to treatment with UGN-102: A substudy of the phase 3 ENVISION trial.
 
John Sfakianos
Consulting or Advisory Role - CG Oncology; Ferring; Pfizer; Urogen pharma
Speakers' Bureau - Natera
Research Funding - IRRISEPT
 
Dimitar Shishkov
Speakers' Bureau - Astellas,BMY
Research Funding - PSI
 
Nikola Mihaylov
No Relationships to Disclose
 
Alexandre Khuskivadze
No Relationships to Disclose
 
Pencho Genov
No Relationships to Disclose
 
Vasyl Terzi
No Relationships to Disclose
 
Max Kates
Honoraria - AUA, UrologyTimes, Medstar, BCAN, Kaplan
Consulting or Advisory Role - Aura, Pfizer, Urogen, Protara, ImmunityBio, Merck, Flashpoint
 
Willliam Huang
Honoraria - UroGen pharma
Consulting or Advisory Role - UroGen pharma
Speakers' Bureau - UroGen pharma
Research Funding - Merck, Urogen, Histosonics, Cysview, Intuitive Surgical,
 
Michael Louie
Employment - UroGen pharma
Stock and Other Ownership Interests - UroGen pharma
 
Sunil Raju
Employment - UroGen Pharma
Leadership - UroGen Pharma
Stock and Other Ownership Interests - UroGen Pharma
Research Funding - UroGen Pharma
Other Relationship - UroGen Pharma employee since August 2022
 
Brent Burger
Employment - UroGen pharma
Stock and Other Ownership Interests - UroGen pharma
 
Andrew Meads
Employment - UroGen Pharma
Stock and Other Ownership Interests - UroGen Pharma
 
Sandip Prasad
Stock and Other Ownership Interests - MetasTx
Consulting or Advisory Role - UroGen pharma
Speakers' Bureau - UroGen pharma
Research Funding - UroGen Pharma, Merck, Genentech
 
The ENVISION Study Group
No Relationships to Disclose